Top Markets
Coin of the day
Gan & Lee Pharmaceuticals. Gan & Lee Pharmaceuticals.

Gan & Lee Pharmaceuticals.

603087
Rank in Stocks #3131
Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused... Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused on the discovery, development, manufacturing, and marketing of insulin analogues within the Chinese market. Their diverse product portfolio encompasses injectable therapies such as Basalin (an insulin glargine), Prandilin (an insulin lispro), Prandilin 25 (another insulin lispro variant), Raplin (an insulin aspart), Raplin 30 (an insulin aspart 30 formulation), and Similin 30 (an insulin injection). Beyond diabetes treatments, the company also offers various medical devices. Established in 1998, Gan & Lee Pharmaceuticals maintains its corporate headquarters in Beijing, People's Republic of China. The organization underwent a name change in April 2005, transitioning from its former identity as Beijing Gan & Lee Biotechnology Co., Ltd.
Share Price
$10.27
Market Cap
$6.14B
Change (1 day)
3.08%
Change (1 year)
3.63%
Country
CN
Trade Gan & Lee Pharmaceuticals. (603087)

Category

P/B ratio for Gan & Lee Pharmaceuticals. (603087)
P/B ratio as of 2026 TTM: 0
According to Gan & Lee Pharmaceuticals. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Gan & Lee Pharmaceuticals. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
7.6976 -
US
1.9116 -
FR
- -
JP
2.0641 -
US
- -
CH